Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUST trial of stopping versus continuing adalimumab in JIA-associated uveitis
2019-000412-29Phase 4Unknown
- Sponsor
- Francis I. Proctor Foundation
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in juvenile idiopathic arthritis-associated uveitis (JIA-U) and juvenile idiopathic arthritis (JIA) comparing Continue adalimumab with Stop adalimumab and receive placebo (2 arms). Primary endpoint: Time to treatment failure. Status: unknown.
02
Drugs
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIA-U)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2019-000412-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000412-29.